BCTX (BriaCell Therapeutics Corp.) Cumulative Company Assets

The linear price action on the total assets chart for BriaCell Therapeutics (BCTX), which currently stands at 22.61, is subject to geopolitical instability that is hindering global trials and component deliveries. High costs associated with the final stages of immunotherapy development are placing significant pressure on financial stability. Looking ahead, the business capitalization will rely on the implementation of the Bria-IMT platform for the treatment of advanced breast cancer.

BriaCell Therapeutics Corp. (BCTX) Aggregate Company Assets: for the period 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for BriaCell Therapeutics Corp (BCTX)

- stock quotes and analyst forecast:

Share Price briacell.com|BCTX - Analyst Consensus Forecast

- business market valuation indicators:

Market Valuation BriaCell Corp|BCTX - Enterprise Value

- company book value details:

Book Value per Share BriaCell|BCTX - Company Book Value|Capitalization to Book Value Ratio briacell.com|BCTX - Company Total Assets

- debt burden and liquidity indicators:

- earnings and market multiples details:

BCTX - Company Net Income

Basic company analysis:briacell.com (BCTX)

BriaCell Therapeutics (BCTX) development of exclusive immunotherapeutic vaccines requires significant resources, which is reflected in the dynamics of total assets and liabilities. This metric, reconstructed via a reverse return on assets (ROA) calculation, allows for an assessment of the issuer's actual material base, while an analysis of total assets in conjunction with debt load reveals the company's true liquidity.

Key competitors